TScan Therapeutics Cuts 75% Workforce, Focuses on Solid‑Tumor T‑Cell Therapy – Shares Fall 11%
How TScan’s 75% workforce cut and shift to in‑vivo solid‑tumour T‑cell therapy is shaking its stock, investor sentiment, and future prospects.
3 minutes to read
